SUNNYVALE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.
Credit Suisse Healthcare Conference, Phoenix, AZ Thursday, 12 November, 2009 at 10 a.m. Mountain Time NASDAQ OMX 23rd Investor Program, London, England Tuesday, 1 December, 2009 at 10.45 a.m. Greenwich Mean Time Piper Jaffray Health Care Conference, New York, NY Wednesday, 2 December, 2009 at 1.30 p.m. Eastern Time
To access the live webcasts for these events, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the schedule start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.
Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.
CONTACTS: For Media Inquiries: For Investor Inquiries: Jared Tipton Jacquie Ross Cepheid Corporate Communications Cepheid Investor Relations Tel: (408) 400-8377 Tel: (408) 400-8329 firstname.lastname@example.org email@example.com
Copyright©2009 PR Newswire.
All rights reserved